Mendaera, a robotics firm, introduced it has been granted FDA 510(okay) clearance for Focalist, a handheld robotic system, which goals to mix handheld robotics with real-time imaging to allow clinicians to position needles with precision.
Mendaera stated the system integrates robotics, ultrasound imaging and superior software program to make medical procedures extra accessible.
Amongst Focalist’s options are touchscreen concentrating on, robotic needle positioning and steady needle depth monitoring, enabling a reproducible process expertise.
Whereas needle placement is used for a wide range of procedures and in a broad vary of scientific settings, the preliminary focus of the system can be in urology. Full commercialization is predicted in 2026.
“Exact placement of needles to carry out a variety of procedures, organ entry, biopsies, vascular entry or remedy supply, as examples, is a really difficult, however foundational approach that underpins most affected person care journeys,” Josh DeFonzo, cofounder and CEO of Mendaera, stated in an announcement.
“Our mission is to make sure that these procedures are delivered safely and effectively throughout the healthcare system by enabling extra suppliers with the boldness wanted to carry out these strategies. Robotics have been proven to extend supplier capabilities in complicated procedures and we intend to reveal that the identical will be true in on a regular basis care.”
THE LARGER TREND
In April, Mendaera collaborated with fellow needle firm Prepare dinner Medical to supply Prepare dinner’s needles as an possibility mixed with the Mendaera robotic.
The collaboration aimed to create “cutting-edge” instruments for needle-based interventions in urological procedures. Prepare dinner’s EchoTip know-how was built-in into Mendaera’s instrumentation choices.
In 2024, EchoNous, an organization specializing in transportable ultrasound know-how, partnered with Mendaera by enabling compatibility between EchoNous’ transportable ultrasound machine Kosmos and Mendaera’s handheld robotic interventional platform.
That very same yr, Mendaera introduced the closing of a $73 million Sequence B funding spherical. The funds had been used to additional the corporate’s efforts to scale robotics and AI throughout mainstream medical procedures.
Mendaera acquired Avail Medsystems’ telepresence know-how final yr. Mendaera utilized its expanded portfolio to extend affected person entry to interventions to assist enhance affected person care inside healthcare programs.
In 2023, Mendaera secured $24 million in Series A funding in a spherical led by Lux Capital.
The corporate stated it will use the funds to open a manufacturing facility to finish growth of its know-how and procure FDA clearance.
Trending Merchandise
